Therapeutic activity of glycoengineered anti-GM2 antibodies to malignant mesothelioma. GM2 expression in a clinical malignant pleural mesothelioma specimen determined by anti-GM2 antibody BIW-8962

2015 ◽  
Vol 106 (1) ◽  
pp. January cover-January cover
Author(s):  
Qi Li ◽  
Wei Wang ◽  
Yusuke Machino ◽  
Tadaaki Yamada ◽  
Kenji Kita ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Malignant Mesothelioma ◽  
Pleural Mesothelioma ◽  
Therapeutic Activity

scholarly journals Mesothelium and Malignant Mesothelioma

2019 ◽  
Vol 7 (2) ◽  
pp. 7 ◽  
Author(s):  
Emilye Hiriart ◽  
Raymond Deepe ◽  
Andy Wessels
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Malignant Mesothelioma ◽  
Pleural Cavity ◽  
Pleural Mesothelioma ◽  
Primary Cancer ◽  
Epithelial Structure

The mesothelium is an epithelial structure derived from the embryonic mesoderm. It plays an important role in the development of a number of different organs, including the heart, lungs, and intestines. In this publication, we discuss aspects of the development of the mesothelium, where mesothelial structures can be found, and review molecular and cellular characteristics associated with the mesothelium. Furthermore, we discuss the involvement of the mesothelium in a number of disease conditions, in particular in the pathogenesis of mesotheliomas with an emphasis on malignant pleural mesothelioma (MPM)—a primary cancer developing in the pleural cavity.

scholarly journals Therapeutic activity of glycoengineered anti‐ GM 2 antibodies against malignant pleural mesothelioma

2014 ◽  
Vol 106 (1) ◽  
pp. 102-107 ◽  
Author(s):  
Qi Li ◽  
Wei Wang ◽  
Yusuke Machino ◽  
Tadaaki Yamada ◽  
Kenji Kita ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma ◽  
Therapeutic Activity

Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion

Lung Cancer ◽  
2001 ◽  
Vol 31 (2-3) ◽  
pp. 303-310 ◽  
Author(s):  
Bruno Castagneto ◽  
Silvia Zai ◽  
Luciano Mutti ◽  
Antonio Lazzaro ◽  
Ruggero Ridolfi ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma ◽  
Therapeutic Activity

Chemosensitivity of newly established human malignant pleural mesothelioma cells: Significant growth inhibition by amrubicin, a novel 9-aminoanthracycline, or cyclooxygenase 2 inhibitor

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e19060-e19060
Author(s):  
T. Hida ◽  
S. Ogawa ◽  
J. Park ◽  
J. Park ◽  
J. Shimizu ◽  
...  
Keyword(s):  
Growth Inhibition ◽  
Cell Lines ◽  
Malignant Pleural Mesothelioma ◽  
Malignant Mesothelioma ◽  
Cyclooxygenase 2 ◽  
Pleural Mesothelioma ◽  
Dependent Manner ◽  
Promising Therapeutic Approach ◽  
Cyclooxygenase 2 Inhibitors

e19060 Background: Malignant pleural mesothelioma is asbestos-related malignancy that is highly resistant to current therapeutic modalities. Survival of patients with malignant mesothelioma is very poor, especially in advanced stage, regardless of a recent advancement of chemotherapeutical modalities of combination with cisplatin and antifolate. Methods: Eleven cell lines derived from malignant mesothelioma were established in our laboratory. Chemosensitivity of these cell lines to nine chemotherapeutic drugs (cisplatin, vinorelbine, irinotecan, gemcitabine, pemetrexed, gefitinib, erlotinib, and amrubicin and its active in vivo substance, amrubicin-13-OH) and four cyclooxygenase 2 inhibitors was tested by MTT assay. Results: Anti-cancer agents, cisplatin, vinorelbine, gemcitabine, gefitinib, or erlotinib, showed little growth inhibition, and pemetrexed and irinotecan showed modest growth inhibition in malignant mesothelioma cells, whereas amrubicin-13-OH showed strong growth inhibition. Cyclooxygenase 2 inhibitors inhibit proliferation of malignant mesothelioma cells in a dose-dependent manner: modest growth inhibition at clinically achievable low concentrations and complete growth inhibition at clinically achievable high concentrations by intrapleural instillation. In addition, enhanced growth suppression was obtained by using amrubicin-13-OH in combination with cyclooxygenase 2 inhibitor. Conclusions: Our study suggests that amrubicin can inhibit proliferation of malignant mesothelioma cells. In addition, the use of a cyclooxygenase 2 inhibitor may be a promising therapeutic approach in the treatment of mesothelioma, because previous studies indicated the presence of increased cyclooxygenase 2 expression in malignant mesothelioma, which is notoriously resistant to chemotherapy. No significant financial relationships to disclose.

scholarly journals Multiplex Soluble Biomarker Analysis from Pleural Effusion

Biomolecules ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. 1113
Author(s):  
Joman Javadi ◽  
Katalin Dobra ◽  
Anders Hjerpe
Keyword(s):  
Pleural Effusion ◽  
Malignant Pleural Mesothelioma ◽  
Malignant Mesothelioma ◽  
Prognostic Markers ◽  
Pleural Cavity ◽  
Asbestos Exposure ◽  
Pleural Mesothelioma ◽  
Diagnostic Biomarkers ◽  
Biomarker Analysis ◽  
Angiopoietin 1

Malignant pleural mesothelioma (MPM) is a highly aggressive and therapy resistant pleural malignancy that is caused by asbestos exposure. MPM is associated with poor prognosis and a short patient survival. The survival time is strongly influenced by the subtype of the tumor. Dyspnea and accumulation of pleural effusion in the pleural cavity are common symptoms of MPM. The diagnostic distinction from other malignancies and reactive conditions is done using histopathology or cytopathology, always supported by immunohistochemistry, and sometimes also by analyses of soluble biomarkers in effusion supernatant. We evaluated the soluble angiogenesis related molecules as possible prognostic and diagnostic biomarkers for MPM by Luminex multiplex assay. Pleural effusion from 42 patients with malignant pleural mesothelioma (MPM), 36 patients with adenocarcinoma (AD) and 40 benign (BE) effusions were analyzed for 10 different analytes that, in previous studies, were associated with angiogenesis, consisting of Angiopoietin-1, HGF, MMP-7, Osteopontin, TIMP-1, Galectin, Mesothelin, NRG1-b1, Syndecan-1 (SDC-1) and VEGF by a Human Premixed Multi-Analyte Luminex kit. We found that shed SDC-1 and MMP-7 levels were significantly lower, whereas Mesothelin and Galectin-1 levels were significantly higher in malignant mesothelioma effusions, compared to adenocarcinoma. Galectin-1, HGF, Mesothelin, MMP-7, Osteopontin, shed SDC-1, NRG1-β1, VEGF and TIMP-1 were significantly higher in malignant pleural mesothelioma effusions compared to benign samples. Moreover, there is a negative correlation between Mesothelin and shed SDC-1 and positive correlation between VEGF, Angiopoietin-1 and shed SDC-1 level in the pleural effusion from malignant cases. Shed SDC-1 and VEGF have a prognostic value in malignant mesothelioma patients. Collectively, our data suggest that MMP-7, shed SDC-1, Mesothelin and Galectin-1 can be diagnostic and VEGF and SDC-1 prognostic markers in MPM patients. Additionally, Galectin-1, HGF, Mesothelin, MMP-7, Osteopontin, shed SDC-1 and TIMP-1 can be diagnostic for malignant cases.

scholarly journals Management of Pleural Effusion Secondary to Malignant Mesothelioma

2021 ◽  
Vol 10 (18) ◽  
pp. 4247
Author(s):  
Valeria Musso ◽  
Cristina Diotti ◽  
Alessandro Palleschi ◽  
Davide Tosi ◽  
Alberto Aiolfi ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Occupational Exposure ◽  
Malignant Pleural Mesothelioma ◽  
Malignant Mesothelioma ◽  
Therapeutic Options ◽  
Pleural Mesothelioma ◽  
Common Cause ◽  
Comprehensive View ◽  
Clinical Challenge

Malignant pleural mesothelioma (MPM) is a highly aggressive pleural tumour which has been epidemiologically linked to occupational exposure to asbestos. MPM is often associated with pleural effusion, which is a common cause of morbidity and whose management remains a clinical challenge. In this review, we analysed the literature regarding the diagnosis and therapeutic options of pleural effusion secondary to mesothelioma. Our aim was to provide a comprehensive view on this subject, and a new algorithm was proposed as a practical aid to clinicians dealing with patients suffering from pleural effusion.

Response to Chemotherapy of Brain Metastases from Malignant Pleural Mesothelioma

1996 ◽  
Vol 82 (5) ◽  
pp. 456-458 ◽  
Author(s):  
Marco Colleoni ◽  
Guido Liessi ◽  
Cesare Avventi ◽  
Francesca Pancheri ◽  
Gigliola Sgarbossa ◽  
...  
Keyword(s):  
Case Report ◽  
Brain Metastases ◽  
Malignant Pleural Mesothelioma ◽  
Malignant Mesothelioma ◽  
Systemic Chemotherapy ◽  
Pleural Mesothelioma ◽  
Complete Regression ◽  
Response To Chemotherapy ◽  
Intracavitary Chemotherapy ◽  
Uncommon Complication

Brain metastases represent an uncommon complication in malignant pleural mesothelioma. A 55-year-old male suffering from malignant mesothelioma and pretreated with intracavitary chemotherapy and radiotherapy was submitted to systemic chemotherapy including lomustine, carboplatin, vinorelbine, fluorouracil and folates after diagnosis of bilateral cerebral deposits. The patient had an impressive response to chemotherapy, with complete regression of related symptoms. This case report represents the first on response to chemotherapy of brain metastases from mesothelioma. It points out that chemotherapy should be further explored in this subset of patients.

scholarly journals Vanishing lung emphysema during chemotherapy for malignant pleural mesothelioma

2018 ◽  
Vol 6 (1) ◽  
Author(s):  
Ivana Castaniere ◽  
Roberto Tonelli ◽  
Sofia Taddei ◽  
Stefania Taschini ◽  
Riccardo Fantini ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Malignant Mesothelioma ◽  
Tobacco Smoke ◽  
Combined Effect ◽  
Pleural Mesothelioma ◽  
Pleural Disease ◽  
Lung Emphysema ◽  
Pleural Malignant Mesothelioma

We report the case of a 79-year-old man with a tobacco smoke-related left dystrophic bullous emphysema that showed a considerable recovery of the cystic abnormalities during chemotherapy for pleural malignant mesothelioma. We suggest that the disappearance of the dystrophic emphysema could be explained by the combined effect of chemotherapy and pleural disease. We briefly review the literature and we discuss the possible mechanism of this unforeseen manifestation.

scholarly journals Survival of Korean Patients with Malignant Pleural Mesothelioma Compensated for the Asbestos Injury Relief

2021 ◽  
Vol 11 (20) ◽  
pp. 9713
Author(s):  
Min-Sung Kang ◽  
Sung-Soo Lee ◽  
Soon-Chan Kwon ◽  
Da-An Huh ◽  
Yong-Jin Lee
Keyword(s):  
Prognostic Factors ◽  
Occupational Exposure ◽  
Malignant Pleural Mesothelioma ◽  
Malignant Mesothelioma ◽  
Asbestos Exposure ◽  
Performance Status ◽  
Smoking History ◽  
Pleural Mesothelioma ◽  
Histological Subtype ◽  
Epidemiologic Characteristics

Background: The purpose of this study was to identify the epidemiologic characteristics and prognostic factors for malignant pleural mesothelioma in Korea, which are currently insufficient. The data were derived from malignant mesothelioma patients who registered under the Asbestos Injury Relief Act; Methods: A total of 728 patients received compensation from the Asbestos Injury Relief Act due to malignant mesothelioma between 2011 and 2015. Of these, 313 patients (43.0%) with malignant pleural mesothelioma were included in the study. The study variables were sex (male, female), age at diagnosis (<59, 60–69, ≥70), smoking history (yes, no), surgery (yes, no), chemotherapy (yes, no), occupational exposure to asbestos (yes, no), and histological subtype (epithelioid, nonepithelioid); Results: Median survival of mesothelioma was 8.0 months (95% confidence interval: 6.2 to 9.8). The 1-year, 2-year, and 5-year survival rates (%) were 43.5%, 23.6%, and 12.5%, respectively. In multivariate analysis of Cox’s proportional hazards model; sex, age, smoking history, occupational asbestos exposure, and histological subtype were not significant prognostic factors, but surgery and chemotherapy combined was a significant predictor; Conclusions: Although the representativeness of these data is limited, our study estimates the epidemiologic characteristics of malignant pleural mesothelioma. Non-occupational exposure had a similar prognosis to occupational asbestos exposure, and there was no sex difference. In addition, it was found that receiving a combination of surgery and chemotherapy affects the survival rate, but there is a limitation in that factors such as performance status, comorbidities, and stage that contribute to survival are not considered.

Sign in / Sign up

Export Citation Format

Share Document